Subcutaneous Injection<sup>2</sup>

ELIGARD is Delivered via

Subcutaneous Injection2

Choosing an Injection Site

The subcutaneous injection allows for numerous injection sites contributing to the patient’s comfort level, both during and after the administration.3

Areas with Sufficient of Subcutaneous Tissue
Features of Subcutaneous Injections (SC)3
  • Greater number of potential injection sites
  • A shorter needle is designed to reach no further than the SC space
  • Decreased muscle mass is not an issue
  • May be administered in a semi-private infusion center setting
Enhanced Patient
Experience with
Flexibility in
Site of Care

ELIGARD can be administered in a semi-private infusion center setting, hospital or physician’s office2

Man in wheelchair
Tap for safety information


ELIGARD® is contraindicated in patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the components of ELIGARD. Anaphylactic reactions to synthetic GnRH or GnRH agonist analogs have been reported in the literature. Transient increase in serum levels of testosterone during treatment may result in worsening of symptoms or onset of new signs and symptoms during the first few weeks of treatment, including bone pain, neuropathy, hematuria, bladder outlet obstruction, ureteral obstruction, or spinal cord compression.

Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH analogs. Monitor blood glucose level and manage according to current clinical practice. Increased risk of myocardial infarction, sudden cardiac death and stroke has also been reported with use of GnRH analogs in men. Monitor for cardiovascular disease and manage according to current clinical practice. Androgen deprivation therapy may prolong the QT/QTc interval. Consider risks and benefits. May cause fetal harm. Convulsions have been observed in patients taking leuprolide acetate with or without a history of predisposing factors. Manage convulsions according to current clinical practice.

ELIGARD may impair fertility in males of reproductive potential.

The most common injection site adverse events are transient burning and stinging, pain, bruising, and erythema. The most common systemic adverse events include mild to severe hot flashes/sweats, malaise and fatigue, weakness, myalgia, dizziness, clamminess, testicular atrophy, and gynecomastia. As with other GnRH agonists, other adverse reactions, including decreased bone density and rare cases of pituitary apoplexy have been reported.


ELIGARD® is indicated for the palliative treatment of advanced prostate cancer.

Please see full Prescribing Information for ELIGARD.


  1. Sartor O. Eur Urol. 2006
  2. ELIGARD® (leuprolide acetate) for injectable suspension 7.5 mg, 22.5 mg, 30 mg, 45 mg prescribing information. Fort Collins, CO: Tolmar Therapeutics, Inc.; 2019.
  3. Prettyman J. Urologic Nursing 2019
  4. Shore N, et al., BJU Int. 2016